- This article examines whether Natera, at around US$197 a share, still aligns with its underlying worth or whether expectations have already been priced in.
- The stock has delivered a 31.7% return over the last year and a large 3-year return of about 3.5x, even though the year-to-date move is a 13.8% decline and the last 30 days show a 5.7% decline.
- Recent coverage around Natera has focused on its position in the pharmaceuticals and biotech space, with investors closely watching how its technology and product pipeline are perceived against peers. That backdrop provides important context for why the 1-year and 3-year returns look very strong, while the shorter-term pullback may suggest a shift in how risk and expectations are being weighed.
- Natera currently has a valuation score of 4 out of 6, which means it screens as undervalued on four separate checks. The next sections will walk through those valuation methods and then finish with a way to assess value that looks beyond any single model.
Approach 1: Natera Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today’s value. It focuses on the cash the business may generate for shareholders rather than short term earnings moves.
For Natera, the model uses a 2 Stage Free Cash Flow to Equity approach built on cash flow projections in dollars. The latest twelve month free cash flow is about $119.3 million. Analysts provide forecasts for the next few years. Beyond that, Simply Wall St extends those projections out to 2035, with estimated free cash flows reaching into the low billions of dollars before discounting.
When all of those projected cash flows are discounted back and added up, the DCF model arrives at an estimated intrinsic value of about US$317.35 per share. Compared with the current share price of roughly US$197, this suggests the stock appears 37.8% undervalued on this methodology.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Natera is undervalued by 37.8%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.
Approach 2: Natera Price vs Sales
For companies where earnings are not the main focus or are still volatile, the P/S ratio is often a useful way to think about value because it compares what you pay for each dollar of revenue rather than profit.
Higher growth expectations and lower perceived risk usually support a higher P/S multiple, while slower growth or higher uncertainty tends to justify a lower one. Natera currently trades on a P/S of 12.13x, compared with the Biotechs industry average of 10.30x and a peer group average of 19.45x.
Simply Wall St’s Fair Ratio of 8.75x is a proprietary estimate of what Natera’s P/S could be given factors such as its growth profile, margins, industry, market cap and risk characteristics. This is more tailored than a simple comparison with peers or the broad industry, which may have very different growth, profitability or balance sheet strength.
Comparing the Fair Ratio of 8.75x with the current 12.13x P/S suggests the shares are trading above that model’s implied level.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Natera Narrative
Earlier it was mentioned that there is an even better way to think about valuation. On Simply Wall St you can use Narratives, which are clear stories that connect your view of Natera’s business to a set of numbers for future revenue, earnings and margins, then translate that into a Fair Value you can compare against today’s price.
A Narrative is your version of the Natera story written in numbers. It links what you believe about its oncology, organ health and genomics opportunity to a forecast and a Fair Value that updates automatically as new earnings reports, news or guidance are incorporated on the Community page used by millions of investors.
For example, one Natera Narrative on the platform assumes a Fair Value of US$115.47 and leans on more cautious assumptions. Another assumes US$300.00 based on a much more optimistic view. By comparing each Fair Value with the current share price, you can decide whether the story you agree with suggests Natera is closer to fully priced or offers more room based on your own expectations.
Do you think there's more to the story for Natera? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com